Ambagon Therapeutics
PrivateLast Round
Series A
Jan 6, 2022
Total Funding Raised
$103M
Company Overview
Ambagon Therapeutics operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Series A round in January 2022.
Ambagon Therapeutics is a biotechnology company that develops small-molecule cancer drugs by stabilizing the interaction of 14-3-3 proteins with oncogenic client proteins.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ambagon Therapeutics Comparables
Compare Ambagon Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Magnet Biomedicine | 92% | |
| Plexium | 89% | |
| SEED Therapeutics | 88% |
For institutional investors. Book with your work email.
Ambagon Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 6, 2022 | ||||
| Seed | Jul 1, 2020 |
For institutional investors. Book with your work email.
Ambagon Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | Series A |
| RA Capital Management | Series A, Seed |
| Droia Ventures | Seed, Series A |
| BioInnovation Capital | Series A |
| AbbVie Ventures | Seed, Series A |
| Citadel | Series A |
| Inkef Capital | Seed, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 6, 2022
$85M round led by Nextech Invest.
- Jul 1, 2020
$18M round led by RA Capital Management.
For institutional investors. Book with your work email.
Ambagon Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ambagon Therapeutics's valuation, stock price, and market status.
Is Ambagon Therapeutics a public or private company?
Ambagon Therapeutics is a private company.
What is the current stock price of Ambagon Therapeutics?
Ambagon Therapeutics is a private company, so its shares have no public market price. Caplight tracks Ambagon Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ambagon Therapeutics worth (valuation)?
Valuation information for Ambagon Therapeutics is not publicly available.
Can I buy Ambagon Therapeutics stock?
Ambagon Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ambagon Therapeutics's last funding round?
Ambagon Therapeutics's most recent funding round was Series A on January 6, 2022.
Who are the main investors in Ambagon Therapeutics?
Key investors in Ambagon Therapeutics include RA Capital Management, Nextech Invest.
Will Ambagon Therapeutics IPO soon?
No public IPO plans have been announced for Ambagon Therapeutics.
How can I track Ambagon Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Ambagon Therapeutics's shares on secondary markets.